Treeman
Senior Member
- Messages
- 663
- Location
- York, England
AIM ImmunoTech Announces Update on Ampligen Long Covid Development Program - Solve ME/CFS Initiative (solvecfs.org)
A Phase 3 prospective, double-blind, randomized, placebo-controlled trial of Ampligen in ME/CFS (AMP-516) produced improvement in exercise tolerance. An analysis of a subset of patients in that trial with early onset of symptoms showed a statistically significant 51.2% positive response
(301) Ampligen: A General Overview and the Plan for ME/CFS & Long Covid - YouTube
I may be late to the game, so apologies if this has already been shared.
A Phase 3 prospective, double-blind, randomized, placebo-controlled trial of Ampligen in ME/CFS (AMP-516) produced improvement in exercise tolerance. An analysis of a subset of patients in that trial with early onset of symptoms showed a statistically significant 51.2% positive response
(301) Ampligen: A General Overview and the Plan for ME/CFS & Long Covid - YouTube
I may be late to the game, so apologies if this has already been shared.